Principal Investigators:~The principal investigators (PIs) will be transplant physicians at all participating U.S. transplant centers.~Study Design:~This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.~Primary Objective:~The primary objective of this study is to examine the incidence of neutrophil recovery of ≥500/mm3 after cord blood transplantation in a multi-institution setting using CBUs that are not Food and Drug Administration (FDA) licensed.~Secondary Objectives:~In patients receiving a non-licensed CBU:~Assess incidence of transmission of infection~Assess incidence of serious infusion reaction~Determine 1 year overall survival after cord blood transplantation~Assess cumulative incidence of acute graft vs. host disease (GVHD) grades II to IV and grades III to IV~Assess cumulative incidence of chronic GVHD~Determine platelet engraftment of >20,000 mcL and >50,000 mcL
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.